ERAS-0015 in combination

Phase 1

ERAS-0015 in combination is one of 3 therapeutic programs targeting Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Solid TumorsRecruiting

Metastatic Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 1

1 2

Erbitux

IImclone

Phase 1

1 3

ERAS-0015 in combination

EErasca, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Metastatic Solid Tumors

NCT06983743

Clinical

Trials by Indication[1]

Metastatic Solid Tumors1 trial

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Recruiting·EErasca, Inc.·Phase 1·NCT06983743·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ERAS-0015 in combination. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ERAS-0015 in combination. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Erasca, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: EErasca, Inc.

ERAS-0015 in combination

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News